Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature
Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature
复制标题
DOI：
10.1093/ndt/gfu258
复制
发表时间：
2015-01-01
影响因子：
6.1
通讯作者：
Ito, Shuichi
中科院分区：
文献类型：
--
作者：
Kamei, Koichi;Takahashi, Masaki;Ito, Shuichi
背景据报道，粒细胞缺乏症是利妥昔单抗治疗的迟发性并发症。然而，肾病综合征患者中这种并发症的确切发生率和危险因素仍不清楚。回顾了2006年2月至2013年4月期间114例难治性肾病综合征患者的213次利妥昔单抗治疗记录，以确定粒细胞缺乏症（定义为中性粒细胞绝对计数<
Background. Agranulocytosis has been reported as a delayed-onset complication of rituximab treatment. However, the exact incidence and risk factors of this complication in patients with nephrotic syndrome remain unknown.Methods. Records of 213 rituximab treatments for 114 patients with refractory nephrotic syndrome between February 2006 and April 2013 were reviewed to identify episodes of agranulocytosis (defined as an absolute neutrophil count of